The October 1, 2018, article by Janjigian et al, entitled "CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer" (*J Clin Oncol* 10.1200/JCO.2017.76.6212), was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Emiliano Calvo's COIs were given as:

Emiliano Calvo

Consulting or Advisory Role: Novartis, GlaxoSmithKline, Astellas Pharma, Roche/Genentech, Eli Lilly/ImClone, Nanobiotix, Pfizer

Speakers' Bureau: Novartis

Research Funding: Boehringer Ingelheim, Roche/Genentech, Bristol-Myers Squibb, Novartis, PsiOxus Therapeutics, Janssen Oncology, Eisai, AbbVie, OncoMed, PharmaMar, Puma Biotechnology, Spectrum Pharmaceuticals, Sanofi, Eli Lilly, Pfizer, Merck, Nektar, Millennium

Travel, Accommodations, Expenses: Eli Lilly, PsiOxus Therapeutics, Novartis

Other Relationship: Pierre Fabre

They should have been given as:

Emiliano Calvo

Employment: START, HM Hospitales Group

Leadership: START

Stock and Other Ownership Interests: START, Oncoart Associated, International Cancer Consultants

Honoraria: HM Hospitales Group

Consulting or Advisory Role: Novartis, **Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, GLG, SERVIER, Amcure** Roche/Genentech, Nanobiotix, Pfizer

Speakers' Bureau: Novartis

Research Funding: Novartis, **AstraZeneca, BeiGene, START**

Travel, Accommodations, Expenses: **Roche/Genentech**

Other Relationship: **President and Founder of Foundation INTHEOS (Investigational Therapeutics in Oncological Sciences)**

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02406>